Please try another search
| YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
|---|---|---|---|---|---|---|
| Growth of 1000 | 1184 | 1037 | 1119 | 1416 | 1695 | 2341 |
| Fund Return | 18.45% | 3.73% | 11.91% | 12.3% | 11.13% | 8.88% |
| Place in category | 26 | 242 | 18 | 114 | 204 | 178 |
| % in Category | 8 | 44 | 8 | 28 | 48 | 65 |
| Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
|---|---|---|---|---|---|---|
| LU0090841692 | 1.41B | 27.67 | 19.99 | 8.67 | ||
| Global Allocation Fund X4 USD | 504.7M | 17.51 | 15.23 | 8.13 | ||
| LU0724617625 | 1.45B | 15.65 | 11.71 | 6.33 | ||
| BlackRock Global Allocation USD A2 | 7.28B | 15.63 | 11.71 | 6.33 | ||
| LU0329592538 | 1.27B | 16.43 | 12.55 | 7.13 |
| Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
|---|---|---|---|---|---|---|
| Robeco BP US Premium Equities I $ | 5.94B | 12.33 | 11.50 | 9.88 | ||
| LU0226953718 | 5.94B | 11.51 | 10.52 | 8.91 | ||
| LU2216803838 | 5.94B | 12.42 | 11.61 | - | ||
| Robeco BP US Premium Equities K $ | 5.94B | 12.33 | 11.50 | 9.88 | ||
| Robeco BP US Premium Equities F $ | 5.94B | 12.20 | 11.35 | 9.73 |
| Name | ISIN | Weight % | Last | Change % | |
|---|---|---|---|---|---|
| BlackRock ICS USD LiqEnvtlyAwr Agcy Inc | IE00BK8MB266 | 3.91 | - | - | |
| Citigroup | US1729674242 | 3.37 | 119.40 | +1.11% | |
| Wells Fargo&Co | US9497461015 | 3.28 | 94.47 | +0.20% | |
| Cardinal Health | US14149Y1082 | 2.82 | 207.37 | +1.06% | |
| SS&Cs | US78467J1007 | 2.63 | 89.10 | +0.21% |
| Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | Buy | Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review